Mar 1, 2021 4:05 pm EST Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15
Feb 3, 2021 8:29 am EST Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin
Jan 20, 2021 8:13 am EST ENZO BIOCHEM’S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTEES
Jan 5, 2021 8:00 am EST ENZO BIOCHEM TO PARTICIPATE IN THE LIFESCI PARTNERS 10TH ANNUAL HEALTHCARE CORPORATE ACCESS EVENT
Jan 4, 2021 7:00 am EST ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR TESTING POOLED SAMPLES ON THREE PLATFORMS INCLUDING COMPANY’S GENFLEX™ PROPRIETARY SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2
Dec 28, 2020 8:00 am EST ENZO RESPONDS AFTER REVIEWING THE POSITION OF INSTITUTIONAL SHAREHOLDER SERVICES
Dec 15, 2020 8:00 am EST Enzo Biochem Hosting Key Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment
Dec 9, 2020 4:01 pm EST Enzo Biochem Reports First Quarter Fiscal 2021 Financial Results and Provides Business Update
Dec 2, 2020 8:00 am EST Enzo Biochem to Report First Quarter 2021 Financial Results on Wednesday, December 9
Nov 25, 2020 8:00 am EST ENZO BIOCHEM ANNOUNCES APPOINTMENT OF IAN B. WALTERS, MD, TO ITS BOARD OF DIRECTORS
